The Business Research Company’s report on the Head And Neck Cancer Diagnostics Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.
What are the key drivers behind the head and neck cancer diagnostics market’s growth in recent years?
The increasing incidence of head and neck cancer is expected to propel the growth of the head and neck cancer diagnostics market going forward. Head and neck cancer is a group of tumors affecting the head and neck region’s tissues and organs. These malignancies include the mouth, pharynx, larynx, salivary glands, nasal cavity, and sinuses. Head and neck cancer diagnostics help head and neck cancer patients diagnose the disease early with various tests, including an incisional biopsy and a barium swallow test. For instance, in February 2023, according to the American Society of Clinical Oncology, a US-based professional organization for physicians and oncology professionals, head and neck cancer made up 4% of all malignancies in the US. Head and neck cancer is predicted to affect 66,920 people in the USA in 2023 (49,190 men and 17,730 women). In 2020, head and neck cancer will affect 562,328 people worldwide. Furthermore, according to head and neck cancer in Australia statistics, there were 5,189 new head and neck cancer cases in 2022. Therefore, the rise in head and neck cancer incidence is driving the growth of the head and neck cancer diagnostics market.
Access Your Free Sample of the Global Head And Neck Cancer Diagnostics Market Report – Get Insights Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=12016&type=smp
How does the future projection of the head and neck cancer diagnostics market size compare to its historical growth?
The head and neck cancer diagnostics market size has grown rapidly in recent years. It will grow from $1.74 billion in 2024 to $2.05 billion in 2025 at a compound annual growth rate (CAGR) of 17.4%. The growth in the historic period can be attributed to tobacco and alcohol consumption, increasing aging population, awareness campaigns, biopsy techniques development, healthcare infrastructure development
The head and neck cancer diagnostics market size is expected to see rapid growth in the next few years. It will grow to $3.87 billion in 2029 at a compound annual growth rate (CAGR) of 17.3%. The growth in the forecast period can be attributed to genomic biomarkers, rising incidence of hpv-related cancers, integration of artificial intelligence (ai), immunotherapy and targeted therapies, healthcare policy and reimbursement changes. Major trends in the forecast period include liquid biopsy dominance, multi-modality diagnostics, point-of-care diagnostics, global collaborations and partnerships, digital pathology integration.
Gain Exclusive Market Insights—Customize Your Research Report Today For Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=12016&type=smp
Which key players are shaping the future of the head and neck cancer diagnostics market?
Major companies operating in the head and neck cancer diagnostics market include F. Hoffmann-La Roche Ltd., Bristol Myers Squibb Co., Abbott Laboratories, Siemens Healthineers AG, BioNTech AG, Koninklijke Philips N.V., GE HealthCare Technologies Inc., Laboratory Corporation of America, Agilent Technologies Inc., Hologic Inc., Illumina Inc., Shimadzu Corporation, Sysmex Corp., Varian Medical Systems Inc., QIAGEN N.V., Exact Sciences Corp., Bio-Techne Corp., Carestream Health Inc., Myriad Genetics Inc., Cepheid Inc., Invitae Corporation, Accuray Inc., Canon Medical Systems Corporation, NanoString Technologies Inc, Asuragen Inc., Caris Life Sciences Inc., HTG Molecular Diagnostics Inc., Oncgnostics GmbH, Perseus Proteomics Inc., VolitionRx Ltd.
What trends will propel the growth and evolution of the head and neck cancer diagnostics market?
Product innovation has emerged as a key trend gaining popularity in the head and neck cancer diagnostic market. Major market players are concentrating their efforts on creating innovative products to strengthen their position in the market. For instance, in May 2023, Alkem Laboratories Ltd., an India-based healthcare company, launched Cetuxa, the world’s first biosimilar for head and neck cancer treatment. Cetuxa is biosimilar to cetuximab, a monoclonal antibody that inhibits the receptor-dependent transduction pathway and has anti-tumor properties. The epidermal growth factor receptor (EGFR) ‘s extracellular domain is where cetuximab binds. Chemotherapy or radiation therapy is frequently combined with cetuximab in clinical practice. Squamous cell carcinoma of the head and neck that is locally advanced, recurring, or metastatic may be treated with it.
Which regions are expected to become dominant players in the head and neck cancer diagnostics market?
North America was the largest region in the head and neck cancer diagnostics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the head and neck cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Order Your Report Now For Swift Delivery
What are the emerging key segments in the head and neck cancer diagnostics market, and how are they evolving?
The head and neck cancer diagnostics market covered in this report is segmented –
1) By Diagnostic Method: Diagnostic Imaging Equipment, Endoscopy Screening Equipment, Biopsy Screening Tests, Dental Diagnostic Methods, Other Diagnostic Methods
2) By Channel: Retail And Specialty Pharmacies, Hospital Pharmacies, Online Pharmacies
3) By End-User: Hospitals, Diagnostic Centers, Other End Users
Subsegments:
1) By Diagnostic Imaging Equipment: Computed Tomography (CT) Scans, Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET) Scans, X-rays
2) By Endoscopy Screening Equipment: Rigid Endoscopes, Flexible Endoscopes, Video Endoscopy Systems
3) By Biopsy Screening Tests: Fine Needle Aspiration (FNA) Biopsy, Core Needle Biopsy, Surgical Biopsy
4) By Dental Diagnostic Methods: Intraoral Cameras, Dental X-rays, Oral Cancer Screening Devices
5) By Other Diagnostic Methods: Molecular Diagnostics, Blood Tests, Genetic Testing
Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12016
What defines the structure and scope of the head and neck cancer diagnostics market?
Head and neck cancer diagnostics refers to the process of detecting and confirming the presence of malignant cells in the head and neck region by a combination of physical examination, imaging tests, medical history evaluation, and tissue biopsy. It is commonly used to treat squamous cell carcinomas, laryngeal cancer, and hypopharyngeal cancer.
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
